摘要:
Compounds of the formula I, in which R1, R2, R3, R4, R5, and R6 have the meanings given in the description, and their physiologically acceptable salts. The compounds are suitable for use, for example, as hypolipidemics.
摘要:
Compounds of the formula I, in which R1, R2, R3, R4, R5, and R6 have the meanings given in the description, and their physiologically acceptable salts. The compounds are suitable for use, for example, as hypolipidemics.
摘要:
The invention relates to 4-Amino-2-ureidopyrimidine-5-carboxamides of the formula I ##STR1## in which R.sup.1 is H or (C.sub.1 -C.sub.8)-alkyl, where one or more H can be replaced by F; R.sup.2 is selected from the group consisting of F, Cl, Br, H, -O-(C.sub.1 -C.sub.8)-alkyl, and -S-(C.sub.1 -C.sub.8)-alkyl, where the alkyl groups have one or more H replaced by F; R.sup.3 is -O-(C.sub.1 -C.sub.8)-alkyl or -S-(C.sub.1 -C.sub.8)-alkyl, where the alkyl groups have one or more H replaced by F; or R.sup.2 and R.sup.3 together form -O-(C.sub.1 -C.sub.5)-alkylene-O-, where the alkylene portion has one or more H replaced by F; and their physiologically tolerable salts. The invention further provides processes for preparing the compounds of formula I. The compounds are suitable for the treatment of disorders of lipid metabolism.
摘要:
Diarylcycloalkyl derivatives and their physiologically acceptable salts and physiologically functional derivatives are disclosed. The compounds include those of formula I, in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparation. The compounds typically have lipid- and/or triglyceride-lowering properties and are suitable, for example, for the treatment of disorders of lipid metabolism, of type II diabetes, and of syndrome X.
摘要:
The use of galacturonic acid and derivatives thereof for preparing a medicament for the treatment of hyperlipidaemia and/or atherosclerosis is described.
摘要:
Use of inhibitors of the cellular Na+/H+ exchanger (NHE) for the production of a medicament for the normalization of serum lipids.The active compounds identified as inhibitors of the cellular Na+/H+ exchanger (NHE) are used for the production of a medicament for the normalization of serum lipids.They are used for the production of a medicament for lowering the blood lipid level and illnesses caused thereby, as well as the endothelial dysfunction syndrome and illness caused thereby.
摘要翻译:使用细胞Na + / H +交换剂(NHE)的抑制剂来制备用于血清脂质标准化的药物。 鉴定为细胞Na + / H +交换体(NHE)的抑制剂的活性化合物用于制备用于血清脂质标准化的药物。 它们用于制备用于降低由此引起的血脂水平和疾病以及由此引起的内皮功能障碍综合征和疾病的药物。
摘要:
Compounds of the formula I, in which R1, R2, R3, R4, R5, and R6 have the meanings given in the description, and their physiologically acceptable salts. The compounds are suitable for use, for example, as hypolipidemics.